References

endofocus

FOCUS Эндокринология

FOCUS. Endocrinology

2713-01772713-0185

ООО "Издательство "Перо"

10.15829/2713-0177-2023-4-23

endofocus-67

Research Article

Статьи

Преимущества агонистов глюкагоноподобного пептида в свете профилактики сердечно-сосудистых и почечных осложнений

Advantages of glucagon-like peptide agonists in the light of prevention of cardiovascular and renal complications

https://orcid.org/0000-0001-6385-540X

Демидова

Т. Ю.

Demidova

T. Yu.

д.м.н., профессор, заведующая кафедрой эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Tatiana Yu. Demidova – Dr. Sc. (Med.), Professor, Head of Endocrinology Department

1 Ostrovitynova street, 117997 Moscow

t.y.demidova@gmail.com

https://orcid.org/0000-0002-8684-6095

Титова

В. В.

Titova

V. V.

ассистент кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Victoria V. Titova – assistant of Endocrinology Department

1 Ostrovitynova street, 117997 Moscow

meteora-vica@mail.ru

https://orcid.org/0000-0002-6899-4457

Скуридина

Д. В.

Skuridina

D. V.

ассистент кафедры эндокринологии лечебного факультета

117997,г. Москва, ул. Островитянова, д. 1, стр. 10

Daria V. Skuridina – assistant of Endocrinology Department

1 Ostrovitynova street, 117997 Moscow

shurpesha@mail.ru

Российский национальный исследовательский медицинский университет им. Н. И. ПироговаPirogov Russian National Research Medical University

2023

27122023

Нейроэндокринология

1825

2024

Демидова Т.Ю., Титова В.В., Скуридина Д.В.

Demidova T.Y., Titova V.V., Skuridina D.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://endofocus.elpub.ru/jour/article/view/67

Агонисты рецепторов глюкагоноподобного пептида-1 (арГПП-1) доказали свои преимущества в стойком снижении гликемии и HbA1c и достижении целевого контроля у пациентов с сахарным диабетом 2 типа (СД2) как монотерапия или в комбинации с другими лекарственными препаратами. Эти препараты также проявляют высокую эффективность в снижении массы тела как для пациентов с СД2, так и без него.

Результаты исследований говорят о потенциале арГПП-1 в снижении сердечно-сосудистых событий, особенно у пациентов с ранее имевшими атеросклеротическими заболеваниями. Хотя при низком риске сердечно-сосудистых заболеваний подобные эффекты могут быть менее очевидны.

Наличие побочных эффектов, особенно со стороны желудочно-кишечного тракта (ЖКТ), высокая стоимость и низкая доступность препаратов могут быть ограничением для их использования. Кроме того, преимущества в отношение возможной профилактики поздних осложнений СД2 внутри группы неоднородны, при наличии у пациента факторов риска преимущества могут иметь препараты с доказанным влиянием на сердечно-сосудистые и почечные исходы. Таким образом, в некоторых случаях пациентам может понадобиться смена препарата внутри данного класса. При этом важно осуществлять плавный переход между препаратами для оптимизации лечения сахарного диабета и минимизации побочных эффектов.

Glucagon-like peptide-1 receptor agonists (arGPP-1) have proven their advantages in persistent reduction of glycemia and HbA1c and achieving targeted control in patients with type 2 diabetes mellitus (DM2) as monotherapy or in combination with other medications. These drugs are also highly effective in reducing body weight for both patients with and without DM2.

The research results indicate the potential of arGPP-1 in reducing cardiovascular events, especially in patients with pre-existing atherosclerotic diseases. Although with a low risk of cardiovascular disease, such effects may be less obvious.

The presence of side effects, especially from the gastrointestinal tract (GI tract), the high cost and low availability of drugs may be a limitation for their use. In addition, the advantages in relation to the possible prevention of late complications of DM2 within the group are heterogeneous, if the patient has risk factors, drugs with proven effects on cardiovascular and renal outcomes may have advantages. Thus, in some cases, patients may need to change the drug within this class. At the same time, it is important to make a smooth transition between drugs to optimize the treatment of diabetes mellitus and minimize side effects.

агонисты рецепторов глюкагоноподобного пептида-1сахарный диабет 2 типасердечно-сосудистые исходы

glucagon-like peptide-1 receptor agoniststype 2 diabetes mellituscardiovascular outcomes

References1

Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34(11):1174–1186. doi:10.1002/phar.1507.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536. doi:10.1111/dom.12849.

American Diabetes Association. Diabetes Care. 2023;46(suppl 1): S1-S298.

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update Samson, Susan L. et al. Endocrine Practice, Volume 29, Issue 5, 305–340.

Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.

Huthmacher JA, Meier JJ, MAN Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis.

Nauck MA, Meier JJ. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019;181(6): R211-R234. doi:10.1530/EJE-19-0566.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375 (19):1834–1844. doi:10.1056/NEJMoa1607141.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827.

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377 (13):1228–1239. doi:10.1056/NEJMoa1612917.

R.A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes, Diabetes Care 28 (5) (2005) 1092–1100.

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225.

Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., … Bekiari, E. (2021). Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism, 23(9), 2116–2124. doi:10.1111/dom.14451.

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102.

Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.JAMA. 2016; 316:500–508. doi: 10.1001/jama.2016.10260.

Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E, Cappola TP; Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.Circ Heart Fail. 2014; 7:673–679. doi: 10.1161/CIRCHEARTFAILURE.114.000346.

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662. doi:10.1016/S2213-8587(21)00203-5.

Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019;21(11):2576–2580. doi:10.1111/dom.13847.

Nauck M.A., Meier J. J., Cavender M. A., Abd El Aziz M., Drucker D. J. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptoragonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.

Pujadas G, Drucker DJ. Vascular biology of glucagon receptor superfamily peptides: complexity, controversy, and clinical relevance.Endocr Rev. 2016: er20161078.

Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.J Card Fail. 2006; 12:694–699. doi: 10.1016/j.cardfail.2006.08.211.

Nathanson D, Frick M, Ullman B, Nyström T. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure.Diabetol Metab Syndr. 2016; 8:5. doi: 10.1186/s13098-015-0116-2.

Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, ThonGutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.J Mol Cell Cardiol. 2015; 89(Pt B):365–375. doi: 10.1016/j.yjmcc.2015.09.018.

Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7): a multicentre, open‐label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605‐617. 10.1016/S2213–8587(18)30104–9.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‐controlled trial. Lancet. 2019;394(10193):131‐138. 10.1016/S0140–6736(19)31150-X.

Davies, M. J. et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39, 222–230 (2016).

Mann, J. F. E. et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post hoc analysis of the SUSTAIN 1–7 randomized controlled trials. Lancet Diabetes Endocrinol. 8, 880–893 (2020).

Bethel MA, Mentz RJ, Merrill P, et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes. 2018;67. (Suppl1):522–P. doi:10.2337/db18-522-P.

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., … McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology. doi:10.1016/s2213-8587(19)30249-9.

Шамхалова М.Ш., Скляник И. А., Шестакова М. В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020;23(1):56–64 [Shamkhalova M. S., Sklyanik I. A., Shestakova M. V. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes mellitus. 2020;23(1):56–64. (In Russ.)] https://doi.org/10.14341/DM12379.

Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., … Fang, Y. (2021). Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Research and Clinical Practice, 177, 108904. doi:10.1016/j.diabres.2021.108904.

Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19(2):216–227. doi:10.1111/dom.12804.

Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–493.

Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev 2019;35: e3070.

Арефьева А.А., Банко В. В., Садовских М. О., Носков С. М. Первый препарат семаглутида в Российской Федерации: результаты открытого рандомизированного исследования фармакокинетики. Медицинский Совет. 2023;(16):77–82. [Arefeva A. N., Banko V. V., Sadovskikh M. O., Noskov S. M. Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial. Meditsinskiy sovet = Medical Council. 2023;(16):77–82. (In Russ.)] https://doi.org/10.21518/ms2023–312.

Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, Carlos Campos; Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clin Diabetes 1 October 2020; 38 (4): 390–402. https://doi.org/10.2337/cd19–0100.

The authors declare that there are no conflicts of interest present.